Electric blanket use and breast cancer

Epidemiology

Volumn 15, Issue 3, 2004, Pages 376-377

  Kundi, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BED; BREAST TUMOR; CASE CONTROL STUDY; ELECTRICITY; ELECTROMAGNETIC FIELD; FEMALE; HUMAN; INCIDENCE; MIDDLE AGED; NOTE; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TIME;

ADULT; AGED; BEDDING AND LINENS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ELECTRICITY; ELECTROMAGNETIC FIELDS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 3142701513     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/01.ede.0000121551.21770.ff     Document Type: Letter

References (10)

1. Sandler DP. On electric blankets and breast cancer [Editorial]. Epidemiology. 2003;14:509.
2. Kabat GC, O’Leary ES, Schoenfeld ER, et al. Electric blanket use and breast cancer on Long Island. Epidemiology. 2003;14:514-520.
3. Stevens RG. Electric power use and breast cancer: a hypothesis. Am J Epidemiol. 1987;125:556-561.
4. Fedrowitz M, Westermann J, Loescher W. Magnetic field exposure increases cell proliferation but does not affect melatonin levels in the mammary gland of female Sprague Dawley rats. Cancer Res. 2002;62:1356-1363.
5. Liburdy RP, Sloma TS, Sokolic R, et al. ELF magnetic fields, breast cancer, and melatonin: 60 Hz fields block melatonin’s oncostatic action on ER+ breast cancer cell proliferation. J Pineal Res. 1993;14:89-97.
6. Blackman CF, Benane SG, House DE. The influence of 1.2 μT, 60 Hz magnetic fields on melatonin- and tamoxifen-induced inhibition of MCF-7 cell growth. Bioelectromagnetics. 2001;22:122-128.
7. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol. 2000;152:950-964.
8. Beral V for the Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
9. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
10. Hulley S, Furberg C, Barrett-Connor E, et al. for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:58-66.